T42.75XAAdverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter

T42.75XA is the ICD-10-CM diagnosis code for adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter. It belongs to category T42 (poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs), block T36-T50 (poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

The 7th character "A" means initial encounter: use it while the patient is receiving active treatment for the condition.

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 791 (Prematurity with Major Problems, relative weight 4.1075), DRG 793 (Full Term Neonate with Major Problems, relative weight 4.2195), DRG 917 (Poisoning and Toxic Effects of Drugs with MCC, relative weight 1.57) and DRG 918 (Poisoning and Toxic Effects of Drugs without MCC, relative weight 0.872), in MDC 15 (Newborns and Other Neonates with Conditions Originating in the Perinatal Period) and MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 995.29 (unspecified adverse effect of other drug, medicinal and biological substance), 995.29 (unspecified adverse effect of other drug, medicinal and biological substance), E936.3 (other and unspecified anticonvulsants causing adverse effects in therapeutic use) and 1 more.